Why do ihc test

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Immunohistochemistry (IHC) tests are performed to detect specific antigens in tissue samples, primarily for cancer diagnosis and research. Developed in the 1940s by Albert Coons, IHC uses antibodies labeled with enzymes or fluorescent dyes to visualize proteins in cells. It helps identify tumor types, such as distinguishing between HER2-positive and HER2-negative breast cancers, guiding targeted therapies. Over 90% of pathology labs worldwide use IHC for routine diagnostics, with applications expanding to infectious diseases and autoimmune disorders.

Key Facts

IHC was first developed in 1941 by Albert Coons using fluorescent antibodies
Over 90% of pathology laboratories globally utilize IHC for diagnostic purposes
IHC can detect specific proteins like HER2 in breast cancer with 95-99% accuracy
Common markers include Ki-67 for cell proliferation and p53 for tumor suppression
IHC testing typically takes 24-48 hours from sample preparation to results

Overview

Immunohistochemistry (IHC) is a laboratory technique that visualizes specific antigens in tissue sections using labeled antibodies. First developed in 1941 by Albert Coons, who pioneered the use of fluorescent antibodies to detect pneumococcal antigens in tissue, IHC has evolved into a cornerstone of diagnostic pathology. The method gained widespread adoption in the 1970s with the development of enzyme-based detection systems like peroxidase-anti-peroxidase (PAP) and avidin-biotin complex (ABC) techniques. Today, IHC is essential for cancer diagnosis, with applications spanning over 200 different protein markers. The global IHC market was valued at approximately $2.1 billion in 2022, reflecting its critical role in modern medicine. Historical milestones include the 1998 FDA approval of HercepTest for HER2 detection in breast cancer, which revolutionized targeted therapy approaches.

How It Works

IHC testing involves multiple precise steps beginning with tissue fixation, typically using formalin, followed by embedding in paraffin and sectioning into thin slices. The process utilizes antigen-antibody interactions where primary antibodies bind to specific target proteins in the tissue. Detection occurs through secondary antibodies conjugated with enzymes like horseradish peroxidase (HRP) or alkaline phosphatase (AP), which produce visible color changes when exposed to chromogenic substrates. Common visualization methods include 3,3'-diaminobenzidine (DAB) producing brown staining and 3-amino-9-ethylcarbazole (AEC) yielding red staining. Automated staining systems introduced in the 2000s have standardized protocols, reducing human error and improving reproducibility. The technique requires careful optimization of antibody dilution, incubation times, and antigen retrieval methods, particularly heat-induced epitope retrieval (HIER) using citrate buffer at 95-100°C for 20-40 minutes.

Why It Matters

IHC testing has transformed cancer diagnosis and treatment by enabling precise tumor classification and personalized medicine. It identifies therapeutic targets like HER2 in breast cancer (present in 15-20% of cases), PD-L1 in various cancers, and hormone receptors in prostate and breast cancers. This directly impacts treatment decisions, with HER2-positive patients receiving trastuzumab therapy showing 50% reduction in recurrence risk. Beyond oncology, IHC detects infectious agents (like HPV in cervical tissue) and autoimmune markers (such as anti-nuclear antibodies). The technique's clinical significance is underscored by its inclusion in major cancer guidelines, including those from the American Society of Clinical Oncology and College of American Pathologists. Ongoing advancements in multiplex IHC allow simultaneous detection of multiple markers, enhancing diagnostic accuracy while conserving precious tissue samples.